AUTHOR=Hu Peng , Huang Jun , Lu Yi , Zheng Murui , Li Haiyi , Duan Xueru , Deng Hai , Zhao Wenjing , Liu Xudong TITLE=Circulating sex hormones and risk of atrial fibrillation: A systematic review and meta-analysis JOURNAL=Frontiers in Cardiovascular Medicine VOLUME=Volume 9 - 2022 YEAR=2022 URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.952430 DOI=10.3389/fcvm.2022.952430 ISSN=2297-055X ABSTRACT=Background: Sex hormones are associated with many cardiovascular risk factors, but their effects on atrial fibrillation (AF) incidence remain unclear. This study systematic review and meta-analysis aimed to evaluate the association of circulating sex hormones with AF risk by pooling available data from observational studies. Methods: A systematic literature for pertinent articles with case-control and cohort designs was conducted via five databases up to 7th July, 2021. A meta-analysis with six cohort studies was conducted separately in men and women. Adjusted relative risk (RR) with 95% confidence interval (CI) was derived by comparing the highest with lowest levels of specific sex hormone and by using a random-effect or fixed-effect model. Heterogeneity was tested using I2 statistic and Q-test. Results: A total of six cohort studies and four case-control studies were included. In meta-analysis of cohort studies, dehydroepiandrosterone sulfate (DHEAS) was associated with a decreased risk of AF in men (RR: 0.729, 95% CI: 0.559 - 0.952, I2=50.0%, P-heterogeneity = 0.157) after combining results from two cohort studies; total testosterone was not associated with any risk of AF in men and in postmenopausal women, and AF risk was not associated with estradiol in men after synthesizing available studies. Conclusions: This study indicates that higher endogenous DHEAS level was associated with lower AF risk in men, whereas total testosterone and estradiol were not associated with AF risk. Longitudinal studies with multiple monitoring are needed to further promulgate the relationship between various circulating sex hormones and AF risk.